The UK life sciences sector is backed by world-class science, £520 million in government commitments, and new private market infrastructure. So why is 94% of late-stage capital still coming from overseas?

JPM Healthcare 2026 is no longer just about deals. It is a signal-setting moment where life sciences, AI, geopolitics and capital converge. What leaders need to understand.